What are the recommended doses of tuberculosis medications, including isoniazid (INH), rifampicin (RIF), pyrazinamide (PZA), and ethambutol (EMB), based on body weight?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 6, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Recommended Doses of Tuberculosis Medications Based on Body Weight

The recommended daily doses for first-line tuberculosis medications are: isoniazid 5-10 mg/kg (maximum 300 mg), rifampicin 10-20 mg/kg (maximum 600 mg), pyrazinamide 15-30 mg/kg (maximum 2000 mg), and ethambutol 15-25 mg/kg (maximum 2500 mg). 1, 2

Standard Daily Dosing for Adults

Drug Daily Dose (mg/kg) Maximum Daily Dose
Isoniazid 5 mg/kg 300 mg
Rifampicin 10 mg/kg 600 mg
Pyrazinamide 15-30 mg/kg 2000 mg
Ethambutol 15 mg/kg 2500 mg

Standard Daily Dosing for Children

Drug Daily Dose (mg/kg) Maximum Daily Dose
Isoniazid 10-15 mg/kg 300 mg
Rifampicin 10-20 mg/kg 600 mg
Pyrazinamide 15-30 mg/kg 2000 mg
Ethambutol 15-25 mg/kg 2500 mg

Weight-Based Considerations

  • For adults weighing <50 kg, rifampicin dose is typically 450 mg daily
  • For adults weighing >50 kg, rifampicin dose is typically 600 mg daily 1
  • For pyrazinamide, adults <50 kg typically receive 1.5 g daily, while those >50 kg receive 2.0 g daily 1

Intermittent Dosing Options

For directly observed therapy (DOT) regimens, higher doses are used less frequently:

Three Times Weekly Dosing

Drug Dose (mg/kg) Maximum Dose
Isoniazid 15 mg/kg 900 mg
Rifampicin 10 mg/kg 600 mg
Pyrazinamide 50-70 mg/kg 3000 mg
Ethambutol 30 mg/kg 2500 mg

Twice Weekly Dosing

Drug Dose (mg/kg) Maximum Dose
Isoniazid 15 mg/kg 900 mg
Rifampicin 10 mg/kg 600 mg
Pyrazinamide 50-70 mg/kg 3000 mg
Ethambutol 45-50 mg/kg 2500 mg

Special Considerations

  • Hepatotoxicity risk: The risk of isoniazid-induced hepatitis increases with dose when used in combination with rifampicin. Evidence suggests that a dose of 5 mg/kg is appropriate and safe for adults 1
  • Ethambutol in children: Ethambutol can be recommended for children aged ≥5 years at a dosage of 15 mg/kg daily without taking more precautions than for adults 1
  • Ethambutol dosing strategy: The American Thoracic Society recommends 25 mg/kg during the intensive phase of treatment (first 8 weeks) followed by 15 mg/kg during the continuation phase 1
  • Liver function monitoring: Liver function should be tested before starting therapy and monitored when clinical signs of hepatotoxicity appear (fever, malaise, vomiting, jaundice, and weight loss) 1

Drug Interactions and Side Effects

  • Rifampicin is an important inducer of hepatic enzymes, which may reduce the effectiveness of other drugs metabolized in the liver, including oral contraceptives 1
  • When used simultaneously, isoniazid and rifampicin can produce hepatitis in 3-4% of patients, typically appearing during the first 2 weeks of treatment 1
  • Pyrazinamide may cause arthralgia related to elevated uric acid levels, which requires monitoring especially in older patients 3

Multidrug-Resistant TB (MDR-TB)

For MDR-TB (resistance to at least isoniazid and rifampicin), patients should be referred to specialized centers with appropriate expertise and laboratory services 1. Treatment requires individualized regimens based on susceptibility testing.

Remember that monitoring for adverse effects is crucial, particularly for hepatotoxicity with isoniazid, rifampicin, and pyrazinamide; optic neuritis with ethambutol; and ototoxicity with injectable agents like streptomycin.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.